JP2000296174A - 眼用レンズ - Google Patents
眼用レンズInfo
- Publication number
- JP2000296174A JP2000296174A JP11106136A JP10613699A JP2000296174A JP 2000296174 A JP2000296174 A JP 2000296174A JP 11106136 A JP11106136 A JP 11106136A JP 10613699 A JP10613699 A JP 10613699A JP 2000296174 A JP2000296174 A JP 2000296174A
- Authority
- JP
- Japan
- Prior art keywords
- photocatalyst
- lens
- ophthalmic lens
- titanium dioxide
- titanium oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 70
- 239000011941 photocatalyst Substances 0.000 claims abstract description 48
- 210000001508 eye Anatomy 0.000 claims abstract description 17
- 239000004408 titanium dioxide Substances 0.000 claims abstract description 16
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000013078 crystal Substances 0.000 claims abstract description 13
- 210000005252 bulbus oculi Anatomy 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 210000000695 crystalline len Anatomy 0.000 claims description 95
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 7
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 abstract 2
- 229910002370 SrTiO3 Inorganic materials 0.000 abstract 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 abstract 1
- 229910044991 metal oxide Inorganic materials 0.000 abstract 1
- ZNOKGRXACCSDPY-UHFFFAOYSA-N tungsten(VI) oxide Inorganic materials O=[W](=O)=O ZNOKGRXACCSDPY-UHFFFAOYSA-N 0.000 abstract 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc oxide Inorganic materials [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 abstract 1
- 238000000576 coating method Methods 0.000 description 18
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 17
- 239000011248 coating agent Substances 0.000 description 17
- 208000002177 Cataract Diseases 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000012790 adhesive layer Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000013032 photocatalytic reaction Methods 0.000 description 8
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 239000010703 silicon Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010014801 endophthalmitis Diseases 0.000 description 4
- 230000004410 intraocular pressure Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000001699 photocatalysis Effects 0.000 description 4
- 229940010747 sodium hyaluronate Drugs 0.000 description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 4
- 229910052719 titanium Inorganic materials 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- 208000008516 Capsule Opacification Diseases 0.000 description 3
- 206010024214 Lenticular opacities Diseases 0.000 description 3
- 238000006303 photolysis reaction Methods 0.000 description 3
- -1 superoxide anions Chemical class 0.000 description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 206010036346 Posterior capsule opacification Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229910006404 SnO 2 Inorganic materials 0.000 description 1
- 229910002367 SrTiO Inorganic materials 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000007146 photocatalysis Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- VEALVRVVWBQVSL-UHFFFAOYSA-N strontium titanate Chemical compound [Sr+2].[O-][Ti]([O-])=O VEALVRVVWBQVSL-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Landscapes
- Eyeglasses (AREA)
- Materials For Medical Uses (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11106136A JP2000296174A (ja) | 1999-04-14 | 1999-04-14 | 眼用レンズ |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11106136A JP2000296174A (ja) | 1999-04-14 | 1999-04-14 | 眼用レンズ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000296174A true JP2000296174A (ja) | 2000-10-24 |
| JP2000296174A5 JP2000296174A5 (show.php) | 2004-11-04 |
Family
ID=14425981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11106136A Pending JP2000296174A (ja) | 1999-04-14 | 1999-04-14 | 眼用レンズ |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2000296174A (show.php) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001035867A3 (de) * | 1999-11-19 | 2001-12-06 | Hampp Norbert | Ophthalmologisches implantat |
| JP2004530940A (ja) * | 2001-06-20 | 2004-10-07 | コロニス ゲーエムベーハー | 光学部品 |
| WO2005065733A1 (ja) * | 2003-12-26 | 2005-07-21 | Hoya Corporation | 眼内レンズおよびその製造方法、ならびに、後発白内障の抑制方法 |
| WO2008059869A1 (en) * | 2006-11-16 | 2008-05-22 | National University Corporation Chiba University | Method of degrading polysaccharide |
| KR101203793B1 (ko) | 2011-07-22 | 2012-11-22 | 경희대학교 산학협력단 | 가시광선 응답형 산화티타늄 광촉매가 코팅된 자가정화 인공수정체의 제조방법 |
| JP2017078777A (ja) * | 2015-10-20 | 2017-04-27 | 株式会社三城ホールディングス | 視力矯正機具 |
| WO2019049651A1 (ja) * | 2017-09-07 | 2019-03-14 | 信越化学工業株式会社 | 光硬化型組成物、ヒドロゲル、及びその成形品 |
-
1999
- 1999-04-14 JP JP11106136A patent/JP2000296174A/ja active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001035867A3 (de) * | 1999-11-19 | 2001-12-06 | Hampp Norbert | Ophthalmologisches implantat |
| JP2004530940A (ja) * | 2001-06-20 | 2004-10-07 | コロニス ゲーエムベーハー | 光学部品 |
| WO2005065733A1 (ja) * | 2003-12-26 | 2005-07-21 | Hoya Corporation | 眼内レンズおよびその製造方法、ならびに、後発白内障の抑制方法 |
| WO2008059869A1 (en) * | 2006-11-16 | 2008-05-22 | National University Corporation Chiba University | Method of degrading polysaccharide |
| JP5354578B2 (ja) * | 2006-11-16 | 2013-11-27 | 国立大学法人 千葉大学 | 多糖類を低分子化する方法 |
| KR101203793B1 (ko) | 2011-07-22 | 2012-11-22 | 경희대학교 산학협력단 | 가시광선 응답형 산화티타늄 광촉매가 코팅된 자가정화 인공수정체의 제조방법 |
| JP2017078777A (ja) * | 2015-10-20 | 2017-04-27 | 株式会社三城ホールディングス | 視力矯正機具 |
| WO2019049651A1 (ja) * | 2017-09-07 | 2019-03-14 | 信越化学工業株式会社 | 光硬化型組成物、ヒドロゲル、及びその成形品 |
| US11987688B2 (en) | 2017-09-07 | 2024-05-21 | Shin-Etsu Chemical Co., Ltd. | Photocurable composition, a hydrogel and a molded product thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI353881B (show.php) | ||
| Xu et al. | Jelly-inspired injectable guided tissue regeneration strategy with shape auto-matched and dual-light-defined antibacterial/osteogenic pattern switch properties | |
| Chen et al. | Nanocatalytic biofunctional MOF coating on titanium implants promotes osteoporotic bone regeneration through cooperative pro-osteoblastogenesis MSC reprogramming | |
| JP5478497B2 (ja) | 新規組成物、ならびに関連する方法、コーティング、および物品 | |
| Lin et al. | Photocatalytic and antibacterial properties of medical‐grade PVC material coated with TiO2 film | |
| Morlando et al. | Development of CeO 2 nanodot encrusted TiO 2 nanoparticles with reduced photocatalytic activity and increased biocompatibility towards a human keratinocyte cell line | |
| CN105209049A (zh) | 抗微生物组合物及其制造方法 | |
| JP2000296174A (ja) | 眼用レンズ | |
| JP2016032628A (ja) | 保育器用フード、これを備える保育器、保育器用親水加工シート、及び保育器用親水加工抗菌膜 | |
| Lam et al. | Radiation cross-linked carboxymethyl sago pulp hydrogels loaded with ciprofloxacin: Influence of irradiation on gel fraction, entrapped drug and in vitro release | |
| Dong et al. | Perspectives on the next generation of sunscreen: safe, broadband, and long-term photostability | |
| Ma et al. | Solid SiO2-sealed mesoporous silica for synergistically combined use of inorganic and organic filters to achieve safe and effective skin protection from all-band UV radiation | |
| JP2020111567A (ja) | シミ改善・美白・保湿に高い効果を発揮するナノ活性剤及びその調製方法 | |
| Guo et al. | Robust antibacterial activity of xanthan-gum-stabilized and patterned CeO2–x–TiO2 antifog films | |
| Filié Haddad et al. | Color stability of maxillofacial silicone with nanoparticle pigment and opacifier submitted to disinfection and artificial aging | |
| Wu et al. | Near-Infrared Responsive Biomimetic Titanate/TiO2–X Heterostructure: A Therapeutic Strategy for Combating Implant-Associated Infection and Enhancing Osseointegration | |
| Nocchetti et al. | Alginate microparticles containing silver@ hydroxyapatite functionalized calcium carbonate composites | |
| US20210403338A1 (en) | Dual light-responsive zinc oxide and preparation method thereof as well as photosensitive coating with antibacterial/osteogenic properties | |
| PL229207B1 (pl) | Kompozycja w postaci płynu do pielęgnacji soczewek kontaktowych i materiałów medycznych | |
| BRPI0613412A2 (pt) | preparação contendo sulfato de bário | |
| KR200360135Y1 (ko) | 나노항균소취제가 피복된 항균 소취성 위생용품. | |
| CN116747154B (zh) | 一种氧化铈基可抵御蓝光的防晒材料及其制备方法 | |
| JP2002225910A (ja) | 液体容器 | |
| WO2006126312A1 (ja) | 光触媒を用いた医療用具 | |
| KR20050112695A (ko) | 나노항균소취제가 피복된 항균 소취성 위생용품과 그제조방법. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20041101 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060228 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060501 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060530 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061003 |